
|Articles|December 12, 2012
Targeted therapy shows efficacy in advanced PCa
An orally bioavailable tyrosine kinase inhibitor demonstrated dramatic and rapid effects on advanced prostate cancer, according to researchers from the University of Michigan Comprehensive Cancer Center, Ann Arbor.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Practical uses of AI across the urologic care continuum
2
Walter Hsiang, MD, discusses insurance-related barriers to kidney stone care
3
The UroOnc Minute: Diet and Prostate Cancer, with Stephen J. Freedland, MD
4
How menstrual cycles influence bladder and pelvic floor symptoms
5




















